Capivasertib (AZD5363) is the FDA‐approved ATP‐competitive AKT inhibitor, demonstrating significant efficacy in suppressing the proliferation of PCa cells, both as a monotherapy and in combination with other treatments [5]. Here, AKT1 is linked to posterior cortical atrophy.